Sanofi (NASDAQ:SNY) Receives Average Rating of “Hold” from Analysts

Sanofi (NASDAQ:SNY) has been given an average recommendation of “Hold” by the fifteen brokerages that are presently covering the stock, Marketbeat Ratings reports. Ten investment analysts have rated the stock with a hold rating, three have issued a buy rating and two have issued a strong buy rating on the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $49.50.

A number of research firms recently commented on SNY. Weiss Ratings upgraded shares of Sanofi from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Wednesday, May 13th. Sanford C. Bernstein raised shares of Sanofi to a “strong-buy” rating in a report on Thursday, March 19th. Citigroup reiterated a “neutral” rating on shares of Sanofi in a research note on Monday, April 13th. BNP Paribas Exane lowered shares of Sanofi from an “outperform” rating to a “neutral” rating and set a $50.00 price objective on the stock. in a report on Monday, April 20th. Finally, Morgan Stanley set a $49.00 target price on Sanofi in a research report on Wednesday, July 8th.

Sanofi Trading Up 1.2%

Shares of NASDAQ:SNY opened at $43.68 on Thursday. The business’s 50-day moving average is $43.30 and its 200 day moving average is $45.56. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.01 and a quick ratio of 0.22. Sanofi has a 1 year low of $40.89 and a 1 year high of $52.68. The firm has a market capitalization of $105.90 billion, a P/E ratio of 12.20, a P/E/G ratio of 1.10 and a beta of 0.34.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the company. CSM Advisors LLC purchased a new position in shares of Sanofi during the 3rd quarter valued at approximately $18,244,000. XY Capital Ltd purchased a new stake in Sanofi during the third quarter worth $1,603,000. SageView Advisory Group LLC acquired a new stake in Sanofi during the third quarter valued at $1,442,000. Jain Global LLC purchased a new position in Sanofi in the third quarter valued at $6,270,000. Finally, Callodine Capital Management LP increased its holdings in Sanofi by 35.5% in the third quarter. Callodine Capital Management LP now owns 698,046 shares of the company’s stock valued at $32,948,000 after buying an additional 182,837 shares in the last quarter. 14.03% of the stock is owned by institutional investors and hedge funds.

About Sanofi

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.